Icad developer of cancer treatments, Wednesday reported positive results of a matched-pair cohort study of 369 early-stage non-melanoma skin cancer patients treated with the company’s Xoft Axxent electronic brachytherapy system (x-rays applied to skin cancer sites) or the Mohs micrographic surgery. The study found that rates of recurrence of cancer were virtually identical.
The study results were published online in the peer-reviewed Journal of Contemporary Brachytherapy. Icad said Mohs micrographic surgery is presently accepted as the most effective technique for removing basal cell carcinoma and squamous cell carcinoma, the two most common skin cancers. Icad said the study results confirm that treatment with electronic brachytherapy can help patients achieve similar low rates of skin-cancer recurrence with excellent cosmetic outcomes compared to Mohs surgery.